A prospective PMS study to validate the sensitivity for change of the D-scale in advanced stages of dementia using the NMDA-antagonist memantine.

Ruther E, Glaser A, Bleich S, Degner D, Wiltfang J.

Department of Psychiatry, 
Georg-August University, 
Gottingen, Germany.
Pharmacopsychiatry 2000 May;33(3):103-8 Related Articles, Links 

Abstract

The present postmarketing surveillance (PMS) study is the first large scale systematic and prospective clinical trial of pharmacotherapeutic intervention in advanced stages of dementia. Within a validation program this study aimed at demonstrating the sensitivity of the D-Scale of change (DS-C) for measuring ADL-function. Efficacy of treatment with the NMDA-antagonist memantine was investigated in 531 patients with advanced dementia employing a parallel group design that stratified patient cohorts by severity according to GDS stages (Reisberg, 1992). Efficacy was determined on two independent levels: by the assessment of the physicians' Clinical Global Impression of Change (CGI-C) at the end of a 6-week observation period, and by the assessment of change in elementary ADL-functions by the caregivers using the D-Scale-of-Change. With the D-Scale-of-Change the caregivers can assess a change in broad functional items, i.e. cognitive and motor functions and also elementary functions of daily life. The effect size of this improvement increased constantly during the observation period. Even in patients of GDS stage 7 an improvement could be measured. These results were also seen by the physicians, who recorded an overall clinical improvement in 75.5% of the patients after 6 weeks. Tolerability evaluations resulted in the ratings "very well" by 59.5% or "well" by 35.0% of the patients. No serious adverse drug reactions occurred. A correlation analysis demonstrated a high congruency of both assessments. Furthermore, the observed time course of these improvements paralleled with the time course of symptomatic benefit by effects of memantine that had been repeatedly demonstrated in randomised, double-blind, placebo-controlled studies in mild to moderate dementia. Together with the evaluation of the scale-properties of the D-Scale for assessment of severity the D-Scale and the D-Scale-of-Change can be regarded as validated.

 | order |

Galantamine Alzheimer's articles              www.AlzheimersTreatments.com

Galantamine  fights Alzheimer's
   In the 1950s, a Bulgarian pharmacologist noticed that local villagers rubbed their foreheads with the snowdrop plant to ease nerve pain. Further investigation led to the isolation of the snowdrop extract galantamine  continue

Galantamine: why galantamine is the best agent for restoring memory
   Galantamine has several advantages over donepezil (Aricept®) and rivastigmine (Exelon®)    continue

Galantamine: can sharpen your mental edge
   Galantamine's positive results in slowing the progression of Alzheimer's disease may be due  continue

Galantamine: helps save Memory
   Galantamine is used in treating Alzheimer's disease, because of its ability   continue

Galantamine: beats Prescription Drugs for combating Mental Decline
  Galantamine is different from donepezil (Aricept®) and rivastigmine (Exelon®) in one very important way, galantamine has the unique ability to increase the receptiveness of nicotinic receptors to acetylcholine  continue

Galantamine: opens the channels of your Memory
   The secret of galantamine's success lies in your brain's nicotinic receptors.  continue

Galantamine:  Protect Brain Function by Enhancing Neurotransmission
   Galantamine has been found to be effective in treating  Alzheimer's disease   continue

Galantamine: Boost Memory
   Galantamine achieves the same effect as drugs such as Aricept or tacrine, but has additional benefits   continue

Galantamine protects Brain funtion
   The primary objective with Alzheimer's is to enhance neurotransmission so as to retain memory  continue
    
Galantamine: food for Mind & Body
   Galantamine is a flower extract that improves memory and perhaps even helps with impotence  continue

Galantamine  may help stave off Dementia
   Dementia is a progressive loss of memory accompanied by significant  continue

Galantamine: Memory Enhancement
   Alzheimer's patients  suffer sharp declines in their brain levels of acetylcholine. Galantamine    continue

Galantamine rescues Brain Cells
   According to a study of 653 Alzheimer's disease patients published in the British Medical Journal, the herbal supplement galantamine "appears to slow the progression of the neurodegenerative condition"  continue

Galantamine: the Old Become Young
   As we age, it becomes harder to learn new things. One explanation is the deterioration of the brain's continue

Galantamine: What's Old with Acetylcholine is New to Us
   Acetylcholine deficiency is characteristic of Alzheimer's disease. The primary treatment is administration of agents like galantamine, an extract from the snowdrop and daffodil plants  continue